It didn’t take long for the street to react to Tandem’s results when they DECREASED full year sales guidance lowering it from $850 million to $865 million to $835 million to $845 million. During the call the company cited three factors that contributed to the reduction in guidance.
1. COVID/Staffing issues in endocrinologists offices
While issues 1 and 3 will change competition will not and one has to wonder whether the Omnipod 5 with its pay as you go model could more dramatically impact sales of the Control IQ then we . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.